Stocks-IBRX-ImmunityBio Inc

IBRX ImmunityBio Inc

6.23 0.62 (11.05%)
Invest
Invest

Overview

Prev Close6.23
Day's Range 5.45 - 6.26
52 Week Range 2.60 - 7.96
Average Volume (3m)1.79M
1-Year Return9.06%
Beta1.6228
Market Cap2.49B
P/E Ratio
Revenue557K
EPS-1.0028
Dividend (Yield)0 (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Created with Highcharts 4.2.7 /Highstock 4.2.722/06/202202/09/202214/11/20223.003.504.004.505.005.506.006.50
Chart times in UTC
Industry Pharmaceuticals Major
CEO Richard Adcock, MBA
Employees 587

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2021: ImmunityBio Inc's revenues increased by 741.44% and amounted to 934.00K. Net income decreased by 278.69% to -349.85M. Net assets decreased by NaN to N/A and EPS decreased from -0.89 to N/A.
IBRX's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
N/A
Net Profit Margin
-138,472.93%
Operating Margin
-62,059.61%
Return On Investment
-114.25%
12/21
03/22
06/22
09/22
Total Revenue
390K
14K
35K
118K
Gross Profit
N/A
N/A
-5.9M
-5.86M
Operating Income
-79.27M
-95.97M
-79.62M
-90.8M
Net Income
-91.55M
-103M
-94.84M
-111.16M